The Crucial Role of Surgical Treatment in BIA-ALCL Prognosis in Early- and Advanced-Stage Patients
- 26 August 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 146 (5) , 530e-538e
Abstract
Background: Studies on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) are trying to optimize medical and surgical treatments for early and advanced stages of this disease. The aim of this article is to share the experience gathered on the authors’ prospectively collected 46 well-documented cases. Methods: Italian physicians are obliged to report BIA-ALCL cases to the Italian Ministry of Health. Because of this cooperation with health care professionals, the competent authority has coordinated and centralized the collection of information for each patient in 46 cases of BIA-ALCL. Statistical analyses with cumulative incidence and corresponding 95 percent confidence interval are provided for each year, dividing the number of new cases that occurred in a defined year and the population at risk of experiencing BIA-ALCL during the same year. Results: The mean time to the onset of symptoms is reduced to 6.4 ± 3.77 years (range, 1 to 22 years). Increased knowledge has also shortened the average time to diagnosis, at 7.2 ± 3.71 years (range, 2 to 22 years). A late seroma appears in 91 percent of cases. The patient who died underwent limited surgery. The Italian incidence has been estimated as 2.8 per 100,000 patients receiving implants (95 percent CI, 0.88 to 4.84) in 2015; 2.1 (95 percent CI, 0.43 to 3.86) in 2016; 3.2 (95 percent CI, 1.11 to 5.31) in 2017; and 3.5 (95 percent CI, 1.36 to 5.78) in 2018. Conclusion: Although the number of cases has risen slightly, BIA-ALCL is still a rare disease with a stable incidence, easily recognized and with a favorable prognosis also in advanced stages if complete surgical excision is performed.Keywords
This publication has 26 references indexed in Scilit:
- Targeted next generation sequencing of breast implant‐associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3ABritish Journal of Haematology, 2016
- Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphomaHaematologica, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell LymphomaJournal of Clinical Oncology, 2016
- Silicone implants and lymphoma: The role of inflammationJournal of Autoimmunity, 2015
- Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomesAnnals of Oncology, 2015
- Mucosal CD30-Positive T-Cell Lymphoproliferative Disorder Arising in the Oral Cavity Following Dental ImplantsInternational Journal of Surgical Pathology, 2015
- Breast implant‐associated anaplastic large cell lymphoma in a patient with Li–Fraumeni syndromeHistopathology, 2015
- Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 PatientsJournal of Clinical Oncology, 2014
- Soft Tissue Anaplastic Large T-Cell Lymphoma Associated with a Metallic Orthopedic Implant: Case Report and Review of the Current LiteratureThe Journal of Foot and Ankle Surgery, 2010